Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia.

Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Abstract Text:

Shin Nakayama,Tokiko Nagamura-Inoue,Kazuaki Yokoyama,Nobuhiro Ohno,Jun Ooi,Satoshi Takahashi,Kaoru Uchimaru,Toru Iseki,Arinobu Tojo,Shin Nakayama,Tokiko Nagamura-Inoue,Kazuaki Yokoyama,Nobuhiro Ohno,Jun Ooi,Satoshi Takahashi,Kaoru Uchimaru,Toru Iseki,Arinobu Tojo,

We compared immunologic parameters of chronic myeloid leukemia (CML) patients in cytogenetic remission receiving imatinib mesylate (STI) treatment, CML patients receiving interferon alpha (IFN-alpha), and healthy volunteers. Each group comprised 14 subjects. Median treatment dosages and durations were 6 x 10(6) IU/week and 174 months, respectively, for IFN-alpha and 400 mg/day and 54 months for STI. The numbers of T-cells were significantly lower in the 2 patient groups (P = .0006), whereas the 3 groups were comparable with respect to the numbers of natural killer cells. Not only the absolute numbers of monocytes and B-cells but also serum immunoglobulin G (IgG) and IgA titers were significantly lower in the STI group than in the IFN-alpha group (P < .0001). For T-cell subsets, the ratio of CD4 T-cells to CD8 T-cells was significantly lower in the IFN-alpha group than in the STI group, but the proportion of CD26(high)CD4+ T-cells among CD4+ cells was significantly higher. Collectively, the 2 therapeutic agents induce a distinct immunologic status in CML patients whose hematopoiesis has returned to normal levels.

Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Publishing Authors By Initials

S Nakayama,T Nagamura-Inoue,K Yokoyama,N Ohno,J Ooi,S Takahashi,K Uchimaru,T Iseki,A Tojo,S Nakayama,T Nagamura-Inoue,K Yokoyama,N Ohno,J Ooi,S Takahashi,K Uchimaru,T Iseki,A Tojo,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: International journal of hematology

VOLUME: 86

Page Numbers: 208-11

Journal Abbreviation: Int. J. Hematol.

ISSN: 0925-5710

DAY: 8

MONTH: Oct

YEAR: 2007

Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9111627

Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia.

AFFILIATION: Department of Hematology/Oncology, Research Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Int J Hematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia Related Publications

• Body composition and respiratory function in healthy non-obese children.
• Central nervous system leukemia on magnetic resonance imaging.
• Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia.
• Leaching behaviour of elements and evaluation of pre-treatment methods for municipal solid waste incinerator residues in column leaching tests.
• On the electronic character of localized singlet 2,2-dimethoxycyclopentane-1,3-diyl diradicals: substituent effects on the lifetime.
• Predictors of the persistence of childhood asthma.
• RETRACTED: Heterogeneous promoter activity of the telomerase reverse transcriptase gene in individual acute myeloid leukemia cells defined by lentiviral reporter assay.
• RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
• Retraction. Heterogeneous promoter activity of the telomerase reverse transcriptase gene in individual acute myeloid leukemia cells defined by lentiviral reporter assay.
• Skin permeation of ketotifen applied from stick-type formulation.
• Specificity of antibodies to single-stranded (ss) DNA in SLE patients with anti-phospholipid syndrome.
• Whey acidic protein (WAP) regulates the proliferation of mammary epithelial cells by preventing serine protease from degrading laminin.
• [False-positive reaction of urinary ketone bodies caused by bucillamine]
• [Severe systemic edema correlated with serum VEGF titer in a patient with angioimmunoblastic T-cell lymphoma]
• [Single-use medical instruments in home care]